LDLR and Hypercholesterolemia: Our engineered HFn variant aims to interfere with the interaction between PCSK9 and LDLR by presenting multiple copies of a PCSK9‐binding domain on the surface of ferritin, with the goal of mitigating the detrimental effects of PCSK9 on LDL‐C clearance and potentially offering a novel approach for the treatment of hypercholesterolemia (Jiang et al., 2018).